StockGlow

CRISPR Therapeutics AG (C2RS34.SA)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

30.45+0.00%Healthcare
Compare C2RS34.SA with
StockGlow Score
7
Bearish
BearishBullish
1 year ago-6.3%

The outlook

CRISPR Therapeutics AG currently reads as bearish based on below its 50- & 200-day averages, 2% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Market cap
$3.00B
52-wk high
40.04
52-wk low
30.26
50-day avg
33.52
200-day avg
33.52
Trailing P/E
—

Similar stocks

0VRQ.LCRISPR Therapeutics AG$47.80-0.42%CRSPN.MXCRISPR Therapeutics AG$811.08+0.00%1CG.FCRISPR Therapeutics AG N$42.21+0.49%ITLC34.SAIntel Corporation$78.45+1.75%M1TA34.SAMeta Platforms, Inc.$99.77+2.22%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy